ArticleNeuro-ophthalmology (Aeolus Press)2026
Ocular Neuromyotonia in Thyroid Eye Disease.
Article in Neuro-ophthalmology (Aeolus Press), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocular neuromyotonia (ONM) in thyroid eye disease (TED) seems to be a rare finding. We present the case of a 61-year-old male TED patient who developed spontaneous transient neuromyotonic infradeviation of the right eye every ~1 minute in the setting of prominent enlargement of the right inferior rectus muscle and restriction of supraduction. Neither carbamazepine or lacosamide were able to abate ONM. Following subsequent TED worsening with almost complete restriction of the right eye, ONM was no longer observed. ONM has been described in 7 TED cases, either in conjunction with underlying restrictive strabismus or in isolation. Chronic compression and inflammation seem to lead to nerve hyperirritability, demyelination, and/or axonal damage and predispose to ONM in TED. Importantly, ONM might develop during active or inactive TED. Voltage gated sodium channel blockers should be used in TED-related ONM, albeit clinical response might be incomplete, suggesting the presence of other mechanism(s), besides ephaptic transmission. Newer neuronal membrane stabilizers acting on sodium and calcium channels (e.g. lamotrigine, oxcarbazepine) as well as newer monoclonal antibodies (e.g. teprotumumab, tocilizumab, infliximab) might play a role in TED-related ONM and their potential therapeutic effect should be investigated in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.